港股異動 | 中藥股繼續走強 中國中藥(0570.HK)大漲超13%
格隆匯1月3日丨中藥股繼續走強,中國中藥(0570.HK)大漲超13%,白雲山漲超3%,同仁堂科技、同仁堂國藥等紛紛上漲。國家醫保局和中醫藥管理局12月30日印發關於醫保支持中醫藥傳承創新發展的指導意見。意見提出,規定將符合條件的中藥飲片、中成藥、醫療機構中藥製劑等納入醫保藥品目錄。將符合《處方管理辦法》和《醫院中藥飲片管理規範》但超出《中華人民共和國藥典》規定常用劑量開具的中藥飲片納入醫保支付範圍。光大證券點評稱:意見從支付端加大了中醫藥發展的保障和支持力度,無疑是一劑重磅加強針;發展中醫藥早已上升為國家重要戰略,而這次指導意見的出台,以更大的力度和更強的決心來全力支持和保障中醫藥產業的傳承創新發展,意義深遠。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.